LOW-VOLUME · FEMALE-LED
nabumetone Side Effects
nabumetone (also sold as Relafen) is a LOW-VOLUME FAERS extract #374 of 524 by FAERS report count. Still opens on FEMALE-LED: 74% of sex-coded reports are female (4,463 F / 1,581 M).
Data updated 2026-05-15
- 6,319
- FAERS reports
Thinner FAERS book - still a temporal association ledger, not proof of cause. Methodology.
nabumetone reporting skew - 74% of sex-coded reports are female (4,463 F / 1,581 M). Volume band LOW-VOLUME #374 of 524 by FAERS report count; caseload WATCHLIST.
Thinner FAERS extract for nabumetone (Relafen) (6,319 reports #374 of 524 by FAERS report count). 74% of sex-coded reports are female (4,463 F / 1,581 M). Sparse books still carry named reaction rows when present; not medical advice.
Counts from the openFDA FAERS extract (2004–2025). Stamps WATCHLIST · DEATH-HEAVY · HOSP-MID · FEMALE-LED.
PAIN leads 461 of 6,319 reports
FEMALE-LED reporters · age peak 45-64
Female-led reporters (74% of sex-coded rows)
Age peak 45-64 (1,956 reports)
FAERS filings rising toward 2025
Reactions in Death Reports
Death-mentioned subset is HEAVY here (360 reports, 5.7%). Top co-reported reactions in that subset - voluntary, not causal.
| Reaction | Reports |
|---|---|
| DEATH | 89 |
| COMPLETED SUICIDE | 77 |
| TOXICITY TO VARIOUS AGENTS | 39 |
| PNEUMONIA | 35 |
| ACUTE KIDNEY INJURY | 31 |
| CARDIAC ARREST | 29 |
| RENAL FAILURE | 29 |
| CARDIO-RESPIRATORY ARREST | 27 |
| SEPSIS | 26 |
| PAIN | 25 |
| RESPIRATORY ARREST | 24 |
| CARDIAC FAILURE CONGESTIVE | 23 |
| CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 21 |
| BLOOD CREATININE INCREASED | 20 |
| NAUSEA | 20 |
| JAUNDICE | 19 |
| MYOCARDIAL INFARCTION | 19 |
| PLEURAL EFFUSION | 18 |
| CHRONIC KIDNEY DISEASE | 17 |
| DISSEMINATED INTRAVASCULAR COAGULATION | 17 |
Reactions in Hospitalization Reports
Hospitalization mid-share (1,504, 23.8%). Co-reported reactions:
| Reaction | Reports |
|---|---|
| PNEUMONIA | 124 |
| PAIN | 119 |
| DYSPNOEA | 113 |
| NAUSEA | 105 |
| FALL | 101 |
| ACUTE KIDNEY INJURY | 97 |
| ANXIETY | 95 |
| DEPRESSION | 84 |
| FATIGUE | 84 |
| BACK PAIN | 77 |
| ARTHRALGIA | 75 |
| DIARRHOEA | 74 |
| HEADACHE | 74 |
| ASTHENIA | 73 |
| CHEST PAIN | 72 |
| VOMITING | 72 |
| PAIN IN EXTREMITY | 68 |
| DIZZINESS | 67 |
| RENAL FAILURE | 67 |
How to read nabumetone FAERS figures (WATCHLIST · DEATH-HEAVY · HOSP-MID)
FAERS holds 6,319 voluntary reports linked to nabumetone (Relafen), 2004-2025. Death is listed on 360 (5.7%). Hospitalization appears on 1,504 (23.8%). Top co-reported indication: Product Used For Unknown Indication.
Sparse extract - named reactions and FEMALE-LED skew still differ by drug; not a complete safety profile.
Read with nabumetone
Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-HEAVY · HOSP-MID stamps.
ABS(total_reports) peer at 6,323 FAERS cases (Δ 4 heavier vs nabumetone); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-MID · FEMALE-LED.
ABS(total_reports) peer at 6,221 FAERS cases (Δ 98 lighter vs nabumetone); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-MID · FEMALE-LED.
ABS(total_reports) peer at 6,445 FAERS cases (Δ 126 heavier vs nabumetone); DEATH-HEAVY · HOSP-MID · SEX-BALANCED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-MID · FEMALE-LED.
ABS(total_reports) peer at 6,450 FAERS cases (Δ 131 heavier vs nabumetone); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-MID · FEMALE-LED.
ABS(death_share) pole at 62.1% death-mentioned reports (Δ 56.4 pp vs nabumetone's DEATH-HEAVY): CASELOAD · HOSP-MID.
nabumetone stamps DEATH-HEAVY · HOSP-MID; FAERS outcome shares are signal-detection rates, not incidence. Read them next to caseload WATCHLIST and the label guide.